Dova Pharmaceuticals (NASDAQ:DOVA) Downgraded to Hold at BidaskClub

BidaskClub lowered shares of Dova Pharmaceuticals (NASDAQ:DOVA) from a buy rating to a hold rating in a report released on Wednesday, June 5th, BidAskClub reports.

DOVA has been the topic of several other research reports. HC Wainwright set a $18.00 price objective on Dova Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, March 5th. Wedbush started coverage on Dova Pharmaceuticals in a research report on Wednesday, May 22nd. They set an outperform rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $30.88.

NASDAQ:DOVA traded up $0.64 during midday trading on Wednesday, hitting $14.10. The company’s stock had a trading volume of 1,642,111 shares, compared to its average volume of 234,385. Dova Pharmaceuticals has a fifty-two week low of $5.62 and a fifty-two week high of $31.63. The company’s 50 day simple moving average is $9.80. The company has a debt-to-equity ratio of 0.20, a quick ratio of 4.27 and a current ratio of 4.46. The company has a market capitalization of $398.09 million, a price-to-earnings ratio of -5.42 and a beta of 1.80.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.10. Dova Pharmaceuticals had a negative net margin of 521.67% and a negative return on equity of 87.20%. The company had revenue of $4.00 million for the quarter, compared to the consensus estimate of $3.46 million. On average, sell-side analysts anticipate that Dova Pharmaceuticals will post -2.03 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. Spark Investment Management LLC lifted its holdings in Dova Pharmaceuticals by 31.8% in the 1st quarter. Spark Investment Management LLC now owns 80,500 shares of the company’s stock valued at $715,000 after purchasing an additional 19,400 shares in the last quarter. Sanders Morris Harris LLC acquired a new stake in shares of Dova Pharmaceuticals in the 1st quarter worth $2,507,000. Vanguard Group Inc. increased its stake in shares of Dova Pharmaceuticals by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 619,604 shares of the company’s stock worth $12,993,000 after acquiring an additional 14,985 shares during the last quarter. Broadfin Capital LLC acquired a new stake in shares of Dova Pharmaceuticals in the 4th quarter worth $2,667,000. Finally, PNC Financial Services Group Inc. increased its stake in shares of Dova Pharmaceuticals by 14,705.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock worth $38,000 after acquiring an additional 5,000 shares during the last quarter. Institutional investors own 30.18% of the company’s stock.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Further Reading: What is the Fibonacci sequence?

Analyst Recommendations for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.